Premature aging and cancer development in transgenic mice lacking functional CYLD.


Journal

Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617

Informations de publication

Date de publication:
10 01 2019
Historique:
received: 09 10 2018
accepted: 17 12 2018
pubmed: 12 1 2019
medline: 21 3 2020
entrez: 12 1 2019
Statut: ppublish

Résumé

CYLD is a deubiquitinating enzyme known for its role as a tumor suppressor whose mutation leads to skin appendages tumors and other cancers. In this manuscript we report that the tumor suppressor CYLD, similarly to other renowned tumor suppressor genes, protects from premature aging and cancer. We have generated transgenic mice expressing the mutant CYLD

Identifiants

pubmed: 30631004
doi: 10.18632/aging.101732
pii: 101732
pmc: PMC6339805
doi:

Substances chimiques

CDKN2A protein, human 0
Cyclin-Dependent Kinase Inhibitor p16 0
NF-kappa B 0
Tumor Necrosis Factor-alpha 0
CYLD protein, mouse EC 3.4.19.12
Deubiquitinating Enzyme CYLD EC 3.4.19.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

127-159

Références

J Cosmet Dermatol. 2005 Jun;4(2):60-72
pubmed: 17166201
Curr Biol. 2001 Apr 17;11(8):558-68
pubmed: 11369200
Aging Cell. 2006 Oct;5(5):379-89
pubmed: 16911562
Breast Cancer Res Treat. 2014 Feb;143(3):447-57
pubmed: 24398777
Aging Cell. 2009 Apr;8(2):152-61
pubmed: 19239418
Cell. 2002 Apr;109 Suppl:S81-96
pubmed: 11983155
Nature. 2002 Jan 3;415(6867):45-53
pubmed: 11780111
Physiol Rev. 1954 Jan;34(1):113-26
pubmed: 13120379
Immunol Today. 1996 Jun;17(6):267-72
pubmed: 8962629
Cancer Prev Res (Phila). 2011 Jun;4(6):851-9
pubmed: 21478324
Oncogene. 1999 Dec 9;18(52):7423-31
pubmed: 10602501
Mutat Res. 2005 Sep 4;577(1-2):252-9
pubmed: 15916783
Oncotarget. 2016 May 17;7(20):29531-47
pubmed: 27121058
JCI Insight. 2016 Jul 21;1(11):
pubmed: 27478875
Genes Dev. 2006 Jul 15;20(14):1868-73
pubmed: 16847346
Aging Dis. 2011 Oct;2(5):437-43
pubmed: 22396892
J Biol Chem. 2004 Dec 31;279(53):55161-7
pubmed: 15496400
Oncogene. 2010 Dec 16;29(50):6522-32
pubmed: 20838385
Cell Death Dis. 2011 Sep 08;2:e208
pubmed: 21900959
Exp Gerontol. 2014 Jun;54:58-66
pubmed: 24440463
Aging Dis. 2011 Dec;2(6):449-65
pubmed: 22396894
Aging (Albany NY). 2014 Nov;6(11):957-74
pubmed: 25553802
J Skin Cancer. 2011;2011:614097
pubmed: 22235375
Aging Cell. 2017 Apr;16(2):219-225
pubmed: 28101907
Differentiation. 1994 Nov;58(1):53-64
pubmed: 7532601
Immun Ageing. 2013 Jun 20;10(1):24
pubmed: 23786653
Curr Drug Targets. 2015;16(4):284-94
pubmed: 25342597
Wiley Interdiscip Rev Syst Biol Med. 2017 Mar;9(2):
pubmed: 27943646
Stem Cells. 2014 Jul;32(7):1917-28
pubmed: 24504902
Nature. 2003 Aug 14;424(6950):793-6
pubmed: 12917689
Genes Dev. 2007 Dec 15;21(24):3244-57
pubmed: 18055696
J Geriatr Oncol. 2016 Sep;7(5):390-6
pubmed: 27567256
Future Oncol. 2011 Feb;7(2):285-97
pubmed: 21345146
J Exp Zool. 1961 Dec;148:205-21
pubmed: 13917600
Neoplasma. 2012;59(1):18-29
pubmed: 22017589
Genes Dev. 2012 Oct 15;26(20):2311-24
pubmed: 23019125
Cell. 2007 Jul 27;130(2):223-33
pubmed: 17662938
Mol Med Rep. 2016 Aug;14(2):1742-50
pubmed: 27357419
Acta Derm Venereol. 1999 Sep;79(5):347-50
pubmed: 10494708
Int Rev Cell Mol Biol. 2016;326:133-74
pubmed: 27572128
Cold Spring Harb Perspect Med. 2015 Jan 05;5(1):a015370
pubmed: 25561721
Trends Endocrinol Metab. 2013 Apr;24(4):184-9
pubmed: 23245767
J Clin Invest. 2004 Nov;114(9):1299-307
pubmed: 15520862
Aging Dis. 2017 Oct 1;8(5):611-627
pubmed: 28966805
Nature. 2003 Aug 14;424(6950):797-801
pubmed: 12917690
Aging (Albany NY). 2014 Nov;6(11):931-43
pubmed: 25553648
J Investig Dermatol Symp Proc. 2009 Aug;14(1):8-14
pubmed: 19675546
Dev Cell. 2007 Sep;13(3):446-54
pubmed: 17765686
Ageing Res Rev. 2009 Jan;8(1):18-30
pubmed: 18692159
J Invest Dermatol. 2013 Jul;133(7):1870-8
pubmed: 23426135
Trends Mol Med. 2010 May;16(5):238-46
pubmed: 20444648
J Invest Dermatol. 1979 Jul;73(1):47-53
pubmed: 448177

Auteurs

Josefa P Alameda (JP)

Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/CIBERONC, Madrid 28040, Spain.
Biomedical Research Institute I+12, 12 de Octubre University Hospital, Madrid 28040, Spain.

Ángel Ramírez (Á)

Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/CIBERONC, Madrid 28040, Spain.
Biomedical Research Institute I+12, 12 de Octubre University Hospital, Madrid 28040, Spain.

Rosa A García-Fernández (RA)

Department of Animal Medicine and Surgery, Faculty of Veterinary, UCM, Madrid 28040, Spain.

Manuel Navarro (M)

Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/CIBERONC, Madrid 28040, Spain.
Biomedical Research Institute I+12, 12 de Octubre University Hospital, Madrid 28040, Spain.

Angustias Page (A)

Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/CIBERONC, Madrid 28040, Spain.
Biomedical Research Institute I+12, 12 de Octubre University Hospital, Madrid 28040, Spain.

José C Segovia (JC)

Division of Hematopoietic Innovative Therapies, CIEMAT/CIBERER/II-FJD, Madrid 28040, Spain.

Rebeca Sanchez (R)

Division of Hematopoietic Innovative Therapies, CIEMAT/CIBERER/II-FJD, Madrid 28040, Spain.

Cristian Suárez-Cabrera (C)

Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/CIBERONC, Madrid 28040, Spain.
Biomedical Research Institute I+12, 12 de Octubre University Hospital, Madrid 28040, Spain.

Jesús M Paramio (JM)

Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/CIBERONC, Madrid 28040, Spain.
Biomedical Research Institute I+12, 12 de Octubre University Hospital, Madrid 28040, Spain.

Ana Bravo (A)

Department of Anatomy, Animal Production and Veterinary Clinical Sciences, Faculty of Veterinary Medicine, University of Santiago de Compostela, Lugo, Spain.

M Jesús Fernández-Aceñero (MJ)

Servicio de Anatomía Patológica Hospital Clínico San Carlos, Departamento de Anatomía Patológica, Facultad de Medicina, UCM, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid 28040, España.

M Llanos Casanova (ML)

Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/CIBERONC, Madrid 28040, Spain.
Biomedical Research Institute I+12, 12 de Octubre University Hospital, Madrid 28040, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH